Opinion|Videos|August 23, 2024
Expert Insights from PALOMA-3: Highlights from ASCO 2024
Author(s)Martin Dietrich, MD, PhD, Wade Iams, MD
Wade T. Iams, MD, outlines insights gleaned from recently presented data from the PALOMA-3 trial in advanced EGFR-mutant non–small cell lung cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on key data from PALOMA and PALOMA-3 recently presented at ASCO 2024.
Advertisement
Related to this article
Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.
Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.
Findings from the phase 1 KANDLELIT-001 study support further investigation of calderasib plus pembrolizumab in KRAS G12C-mutated metastatic NSCLC.
Initial data from the ROSETTA Lung-107 trial support further study of pumitamig in metastatic NSCLC previously managed with an immunotherapy-based regimen.
Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population.
Data from the phase 3 Krascendo 1 trial support divarasib as a new standard in previously treated KRAS G12C–mutated non–small cell lung cancer.
Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.
Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
2
Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study
3
Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer
4
Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC
5